A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
- Conditions
- Urothelial Cancer
- Registration Number
- NCT05366725
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 106
Inclusion Criteria:<br><br> 1. Patients with a diagnosis of locally advanced or metastatic UC, either de novo or<br> relapsed<br><br> 2. Patients received 1L platinum-based chemotherapy and had stable disease, partial<br> response, or complete response to this treatment<br><br> 3. Patients received avelumab as indicated as a monotherapy for the first-line<br> maintenance treatment of adult patients with locally advanced or metastatic UC who<br> are progression-free following platinum-based chemotherapy<br><br> 4. Patients aged =18 years on the date that they commenced avelumab -<br><br>Exclusion Criteria:<br><br> 1. Patients whose hospital records are not available for review<br><br> 2. Patients who are receiving an investigational medicinal product as part of a<br> clinical trial at the time of maintenance therapy with avelumab
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Real world overall survival
- Secondary Outcome Measures
Name Time Method Real world progression free survival;Adverse events explicitly attributed to avelumab;All-cause healthcare resource burden